Teva Pharmaceutical Industries (NYSE:TEVA) Raised to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research note published on Thursday morning.

A number of other analysts also recently weighed in on the stock. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Finally, Jefferies Financial Group upped their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.89.

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of NYSE TEVA opened at $17.95 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries has a 12 month low of $8.06 and a 12 month high of $19.08. The firm has a market capitalization of $20.34 billion, a PE ratio of -46.02, a price-to-earnings-growth ratio of 1.20 and a beta of 0.88. The firm has a fifty day simple moving average of $17.97 and a two-hundred day simple moving average of $16.63.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Equities analysts expect that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently made changes to their positions in TEVA. New Covenant Trust Company N.A. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $28,000. EntryPoint Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $30,000. UMB Bank n.a. boosted its holdings in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.